Citations

Clear

139 citation(s) found for "Anderson, Kenneth C".

Gene expression signatures of conventional prognostic factors in multiple myeloma
Haug, Janine , Shammas, Masood A. , Lacy, Martha Q. , Munshi, Nikhil C. , Kumar, Subodh , Rajkumar, S. Vincent , Li, Chaofan , Dispenzieri, Angela , Gertz, Morie A. , Witzig, Thomas E. , Anderson, Kenneth C.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 6606-6606

10.1200/jco.2005.23.16_suppl.6606 Get It

Immune Therapies in Multiple Myeloma
Kumar, Shaji , Anderson, Kenneth C.

Mayo Clinic

Clinical Cancer Research | November 15, 2016 | Volume: 22 | Issue: 22 | Pages: 5453-5460

10.1158/1078-0432.ccr-16-0868 | PMID 28151713 Get It

Abstract Treatment paradigms have changed rapidly for multiple myeloma, and immune therapies have taken center stage. Advances in therapies for myeloma have led to a dramatic improvement in the survival of patients with this incurable malignancy. The immune system is significantly impaired in patients with myeloma as a result of the disease leading to suppression of normal plasma cells as well the negative effects on cellular immunity. Given this scenario, immune approaches have not been successful until recently. Monoclonal antibodies directed against CD38 (daratumumab) and SLAMF7 (elotuzumab) are already in the clinic, and several other antibodies directed against different plasma cell antigens are under evaluation. Although immune checkpoint inhibition with PD-1 inhibitors had no clinical efficacy when the inhibitors were used as single agents, it has led to some dramatic results when the inhibitors are combined with immunomodulatory drugs such as lenalidomide and pomalidomide. Vaccination strategies have shown in vivo immune responses but no clear clinical efficacy. Newer approaches to vaccination with multiple antigens, used in combinations with immunomodulatory drugs and in the setting of minimal residual disease, have all increased possibility of this approach succeeding. Ex vivo effector cell expansion also appears to be promising and is in clinical trials. Finally, a chimeric antigen receptor T-cell approach appears to have some promise based on isolated reports of success and remains an area of intense investigation. Immune-based approaches can potentially augment or even supplant some of the current approaches and, given the low toxicity profile, may hold great potential in the early treatment of precursor-stage diseases. Clin Cancer Res; 22(22); 5453–60. ©2016 AACR. See all articles in this CCR Focus section, “Multiple Myeloma: Multiplying Therapies.”
A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci
Rand, Kristin A. , Song, Chi , Déan, Eric, Serie, Daniel, Curtin, Karen , Sheng, Xin , Huff, Carol Ann , Bernal‐Mizrachi, Leon , Tomasson, Michael H. , Pawlish, Karen , Peters, Edward , Stram, Alex , Edlund, Christopher K., Conti, David V. , Zimmerman, Todd M., Hwang, Amie E. , Huntsman, Scott , Graff, John, Kong, Yinfei , Pregja, Silvana, Berndt, Sonja I. , Blot, William J. , Carpten, John D. , Chu, Lisa W., Diver, W. Ryan , Stevens, Victoria L. , Lieber, Michael R. , Goodman, Phyllis J. , Hennis, Anselm , Hsing, Ann W. , Mehta, Jayesh, Klein, Eric A. , Leske, Cristina, Murphy, Adam B. , Nemesure, Barbara , Strom, Sara S., Vij, Ravi , Rybicki, Benjamin A. , Stanford, Janet L. , Signorello, Lisa B., Witte, John S. , Bhatti, Parveen , Hu, Jennifer J. , Nyante, Sarah J. , Birmann, Brenda M. , Atanackovic, Djordje , Glenn, Martha, Jones, Brandt, Tricot, Guido , Kumar, Shaji , Wolf, Jeffrey L. , Halverson, Sandra L. , Rothman, Nathaniel , Brooks‐Wilson, Angela , Kolonel, Laurence N. , Severson, Richard K., Janakiraman, Nalini, Terebelo, Howard R. , Brown, Elizabeth E. , Roos, Anneclaire J. De , Mohrbacher, Ann , Spinelli, John J. , Munshi, Nikhil C. , Levy, Joan, Zonder, Jeffrey A. , Orlowski, Robert Z. , Camp, Nicola J. , Vachon, Celine M. , Ziv, Elad , Hazelett, Dennis J. , Haiman, Christopher A. , Serie, Daniel J, Hu, Donglei , Ailawadhi, Sikander , Singhal, Seema , Bock, Cathryn Hufford , Berg, David Van Den , Nooka, Ajay K. , Casey, Graham , Kittles, Rick A. , Kolb, Suzanne , Neslund-Dudas, Christine M , Ambrosone, Christine B. , John, Esther M. , Bernstein, Leslie , Zheng, Wei , Olshan, Andrew F. , Ziegler, Regina G. , Bandera, Elisa V. , Ingles, Sue A. , Press, Michael F. , Cannon‐Albright, Lisa , Martin, Thomas G. , Rothman, Nathaniel , Rajkumar, S. Vincent , Chanock, Stephen Jacob , Slager, Susan L. , Colditz, Graham A. , Giles, Graham G. , Chiu, Brian C.‐H. , Anderson, Kenneth C. , Orlowski, Robert Z. , Lonial, Sagar , Vachon, Celine M. , Stram, Daniel O. , Cozen, Wendy , Hazelett, Dennis J , Brooks-Wilson, Angela R , Klein, Eric A , De Roos, Anneclaire J , Nyante, Sarah , Bhatti, Parveen , Birmann, Brenda M , Ziv, Elad , Conti, David V

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 2, 2016 | Volume: 25 | Issue: 12 | Pages: 1609-1618

10.1158/1055-9965.epi-15-1193 | PMID 27587788 Get It

Abstract Background: Genome-wide association studies (GWAS) in European populations have identified genetic risk variants associated with multiple myeloma. Methods: We performed association testing of common variation in eight regions in 1,318 patients with multiple myeloma and 1,480 controls of European ancestry and 1,305 patients with multiple myeloma and 7,078 controls of African ancestry and conducted a meta-analysis to localize the signals, with epigenetic annotation used to predict functionality. Results: We found that variants in 7p15.3, 17p11.2, 22q13.1 were statistically significantly (P < 0.05) associated with multiple myeloma risk in persons of African ancestry and persons of European ancestry, and the variant in 3p22.1 was associated in European ancestry only. In a combined African ancestry–European ancestry meta-analysis, variation in five regions (2p23.3, 3p22.1, 7p15.3, 17p11.2, 22q13.1) was statistically significantly associated with multiple myeloma risk. In 3p22.1, the correlated variants clustered within the gene body of ULK4. Correlated variants in 7p15.3 clustered around an enhancer at the 3′ end of the CDCA7L transcription termination site. A missense variant at 17p11.2 (rs34562254, Pro251Leu, OR, 1.32; P = 2.93 × 10−7) in TNFRSF13B encodes a lymphocyte-specific protein in the TNF receptor family that interacts with the NF-κB pathway. SNPs correlated with the index signal in 22q13.1 cluster around the promoter and enhancer regions of CBX7. Conclusions: We found that reported multiple myeloma susceptibility regions contain risk variants important across populations, supporting the use of multiple racial/ethnic groups with different underlying genetic architecture to enhance the localization and identification of putatively functional alleles. Impact: A subset of reported risk loci for multiple myeloma has consistent effects across populations and is likely to be functional. Cancer Epidemiol Biomarkers Prev; 25(12); 1609–18. ©2016 AACR.
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Sonneveld, Pieter , Avet‐Loiseau, Hervé , Usmani, Saad Z. , Moreau, Philippe , Attal, Michel , Kyle, Robert A. , Caers, Jo , Hillengaß, Jens , Miguel, Jesús F. San , Donk, Niels W.C.J. van de , Bladé, Joan , Durie, Brian G.M. , Goldschmidt, Hartmut , Mateos, María‐Victoria , Palumbo, Antonio , Orlowski, Robert Z. , Lonial, Sagar , Siegel, David S. , Anderson, Kenneth C. , Chng, Wee Joo , Einsele, Hermann , Orlowski, Robert Z. , Moreau, Philippe , San-Miguel, Jesus , Usmani, Saad

Mayo Clinic

Blood | March 22, 2016 | Volume: 127 | Issue: 24 | Pages: 2955-2962

10.1182/blood-2016-01-631200 | PMID 27002115 Get It

AbstractThe International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q) were identified that confer poor prognosis. The prognosis of patients showing these abnormalities may vary with the choice of therapy. Treatment strategies have shown promise for HR cytogenetic diseases, such as proteasome inhibition in combination with lenalidomide/pomalidomide, double autologous stem cell transplant plus bortezomib, or combination of immunotherapy with lenalidomide or pomalidomide. Careful analysis of cytogenetic subgroups in trials comparing different treatments remains an important goal. Cross-trial comparisons may provide insight into the effect of new drugs in patients with cytogenetic abnormalities. However, to achieve this, consensus on definitions of analytical techniques, proportion of abnormal cells, and treatment regimens is needed. Based on data available today, bortezomib and carfilzomib treatment appear to improve complete response, progression-free survival, and overall survival in t(4;14) and del(17/17p), whereas lenalidomide may be associated with improved progression-free survival in t(4;14) and del(17/17p). Patients with multiple adverse cytogenetic abnormalities do not benefit from these agents. FISH data are implemented in the revised International Staging System for risk stratification.
American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine
Kattan, Michael W. , Hess, Kenneth R. , Amin, Mahul B. , Lü, Ying , Moons, Karl G.M., Gershenwald, Jeffrey E. , Gimotty, Phyllis A. , Guinney, Justin , Halabi, Susan , Lazar, Alexander J. , Mahar, Alyson , Weiser, Martin R. , Compton, Carolyn C. , Core, members of the AJCC Precision Medicine, Compton, Carolyn, Patel, Tushar P , Sargent, Daniel J. , Core, members of the AJCC Precision Medicine, Mahar, Alyson L , Lazar, Alexander J , Halabi, Susan , Lu, Ying , Kattan, Michael W

Mayo Clinic

CA: A Cancer Journal for Clinicians | January 19, 2016 | Volume: 66 | Issue: 5 | Pages: 370-374

10.3322/caac.21339 | PMID 26784705 Get It

The American Joint Committee on Cancer (AJCC) has increasingly recognized the need for more personalized probabilistic predictions than those delivered by ordinal staging systems, particularly through the use of accurate risk models or calculators. However, judging the quality and acceptability of a risk model is complex. The AJCC Precision Medicine Core conducted a 2‐day meeting to discuss characteristics necessary for a quality risk model in cancer patients. More specifically, the committee established inclusion and exclusion criteria necessary for a risk model to potentially be endorsed by the AJCC. This committee reviewed and discussed relevant literature before creating a checklist unique to this need of AJCC risk model endorsement. The committee identified 13 inclusion and 3 exclusion criteria for AJCC risk model endorsement in cancer. The emphasis centered on performance metrics, implementation clarity, and clinical relevance. The facilitation of personalized probabilistic predictions for cancer patients holds tremendous promise, and these criteria will hopefully greatly accelerate this process. Moreover, these criteria might be useful for a general audience when trying to judge the potential applicability of a published risk model in any clinical domain. CA Cancer J Clin 2016;66:370–374. © 2016 American Cancer Society.
Abstract 4629: Multiple myeloma susceptibility loci examined in African and European ancestry populations
Rand, Kristin A. , Song, Chi , Déan, Eric, Serie, Daniel, Curtin, Karen , Hazelett, Dennis J. , Hwang, Amie E. , Sheng, Xin , Stram, Alex , Huff, Carol Ann , Bernal‐Mizrachi, Leon , Roos, Anneclaire De, Pawlish, Karen , Peters, Edward , Bock, Catherine, Conti, David V. , Zimmerman, Todd M., Huntsman, Scott , Graff, John, Mehta, Jayesh, Janakiraman, Nalini, Severson, Richard K., Brown, Elizabeth E. , Kolonel, Laurence N. , Henderson, Brian E., Spinelli, John J., Zonder, Jeffrey A. , Camp, Nicola J. , Vachon, Celine M. , Stram, D. O., Haiman, Christopher A. , Berg, David Van Den , Tomasson, Michael H. , Ailawadhi, Sikander , Singhal, Seema , Colditz, Graham A. , Chanock, Stephen Jacob , Lieber, Michael R. , Klein, Eric A. , Brooks‐Wilson, Angela , Rajkumar, S. Vincent , Slager, Susan L. , Giles, Graham G. , Chiu, Brian C.‐H. , Anderson, Kenneth C. , Orlowski, Robert Z. , Lonial, Sagar , Vachon, Celine M. , Ziv, Elad , Cozen, Wendy , Hazelett, Dennis J , Conti, David V

Mayo Clinic

Cancer Research | August 5, 2015 | Volume: 75 | Issue: 15_Supplement | Pages: 4629-4629

10.1158/1538-7445.am2015-4629 Get It

Abstract Genome-wide association studies (GWAS) of multiple myeloma (MM) in Northern Europeans have identified seven novel risk loci (2p23.3, 3p22.1, 3q26.2, 6p21.33, 7p15.3, 17p11.2, 22q13.1). We performed a multiethnic meta-analysis of these regions in 1,274 MM patients and 1,486 controls of European ancestry (EA) and 1,049 MM patients and 7,080 controls of African ancestry (AA), leveraging the differential linkage-disequilibrium of these populations in order to better localize the putative functional variants. We observed directionally consistent effects for all seven index SNPs in both populations, with four significantly associated (p<0.05) with risk in EAs (3p22.1, 7p15.3, 17p11.2, 22q13.1), and two significantly associated with risk in AAs (7p15.3 and 22q13.1). In a fixed effects meta-analysis of six regions (excluding the HLA region on chromosome 6), variation in five of the regions (2p33.3, 3p22.1, 7p15.3, 17p11.2, 22q13.1) had statistically significant associations with risk (Table 1). In one region, the index variant had the strongest association [rs4487645 at 7p15.3, (OR = 1.30, p = 8.7×10−8)]. Five of the six most significantly associated variants identified in the multiethnic analyses overlapped with biologically relevant features indicating regulatory activity based on CD20+ (B lymphocyte) cells, showing evidence of potential function; those included a missense variant in (17p11.2, rs34562254, Pro251Leu) in TNFRSF13B, which encodes a lymphocyte-specific protein in the tumor necrosis factor receptor family that interacts with the NF-kb pathway. Our study shows that these regions are important in MM risk across ethnicities and further supports the use of multiple ethnic groups in genetic studies to enhance identification of risk variants. Table 1.Most significant associations for each region in the multiethnic meta-analysis.Individuals of European AncestryIndividuals of African AncestryMulitethnic Metar2 with IndexcCHRSNPRAaFreqbORP-valueFreqbORP-valueORP-valueP-het2rs732075G0.591.222.0×10−30.621.122.0×10−21.162.6×10−40.280.09/0.283rs73069394A0.191.243.0×10−30.621.181.5×10−21.201.3×10−50.550.77/0.963rs12637184G0.761.136.0×10−20.921.192.7×10−11.151.0×10−20.640.94/1.007rs4487645C0.671.237.0×10−40.891.485.5×10−51.308.7×10−80.07-d17rs34562254A0.121.452.4×10−50.131.212.2×10−31.312.5×10−60.120.33/0.9022rs139400T0.491.224.0×10−40.531.172.1×10−31.191.2×10−60.630.63/0.96aRisk allelebFrequency of the risk allele in European and African ancestry studiescr2 metrics based on 1000 Genomes Project AFR/EUR populationsdIndex SNP Citation Format: Kristin A. Rand, Chi Song, Eric Dean, Daniel Serie, Karen Curtin, Dennis Hazelett, Amie E. Hwang, Xin Sheng, Alex Stram, David J. Van Den Berg, Carol Ann Huff, Leon Bernal-Mizrachi, Michael H. Tomasson, Sikander Ailawadhi, Anneclaire De Roos, Seema Singhal, Karen Pawlish, Edward Peters, Catherine Bock, David V. Conti, Graham Colditz, Todd Zimmerman, Scott Huntsman, John Graff, African Ancestry Prostate Cancer GWAS Consortium,African Ancestry Breast Cancer GWAS Consortium, Stephen J. Chanock, Michael Lieber, Jayesh Mehta, Eric A. Klein, Nalini Janakiraman, Richard K. Severson, Angela R. Brooks-Wilson, Vincent Rajkumar, Elizabeth E. Brown, Laurence Kolonel, Susan Slager, Brian E. Henderson, Graham G. Giles, John J. Spinelli, Brian Chiu, Kenneth C. Anderson, Jeffrey Zonder, Robert Z. Orlowski, Sagar Lonial, Nicola Camp, Celine Vachon, Elad Ziv, Dan O. Stram, Christopher A. Haiman, Wendy Cozen. Multiple myeloma susceptibility loci examined in African and European ancestry populations. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4629. doi:10.1158/1538-7445.AM2015-4629
The Investigational Proteasome Inhibitor Ixazomib for the Treatment of Multiple Myeloma
Richardson, Paul G. , Moreau, Philippe , Laubach, Jacob P. , Gupta, Neeraj , Hui, Ai-Min, Miguel, Jesús F. San , Kumar, Shaji , Richardson, Paul Gerard Guy , Anderson, Kenneth C. , Gupta, Neeraj , Moreau, Philippe , San-Miguel, Jesus

Mayo Clinic

Future Oncology | April 2, 2015 | Volume: 11 | Issue: 8 | Pages: 1153-1168

10.2217/fon.15.9 | PMID 25832873 Get It

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Palumbo, Antonio , Bringhen, Sara , Mateos, María‐Victoria , Larocca, Alessandra , Kumar, Shaji , Offidani, Massimo , Evangelista, Andrea , Zweegman, Sonja , Musto, Pellegrino , Terpos, Evangelos , Belch, Andrew , Hájek, Roman , Stewart, A. Keith, Moreau, Philippe , Durie, Brian G.M. , Dimopoulos, Meletios Α. , Miguel, Jesús F. San , Richardson, Paul G. , Sonneveld, Pieter , Facon, Thierry T.F. , McCarthy, Philip L. , Lonial, Sagar , Zweegman, Sonja , Ludwig, Heinz , Anderson, Kenneth C. , Einsele, Hermann , Landgren, Ola , Richardson, Paul Gerard Guy , Rajkumar, S. Vincent , Hajek, Roman , Dimopoulos, Meletios A , Moreau, Philippe , Terpos, Evangelos , San-Miguel, Jesus

Mayo Clinic

Blood | January 28, 2015 | Volume: 125 | Issue: 13 | Pages: 2068-2074

10.1182/blood-2014-12-615187 | PMID 25628469 Get It

Key Points Elderly patients with myeloma are heterogeneous and assessment strategies are needed to define the frailty profile. The proposed frailty score aims to better assess patients and provide them with more suitable therapies.
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
Dimopoulos, Meletios Α. , Kastritis, Efstathios , Owen, Roger G., Kyle, Robert A. , Morra, Enrica, Leleu, Xavier , García‐Sánz, Ramón , Munshi, Nikhil C. , Terpos, Evangelos , Ghobrial, Irene M. , Morel, Pierre , Maloney, David G. , Rummel, Mathias , Leblond, Véronique , Advani, Ranjana H. , Kyriakou, Charalampia , Barlogie, Bart , Gregory, Stephanie A., Kimby, Eva , Merlini, Giampaolo , Landgren, Ola , Anderson, Kenneth C. , Gertz, Morie A. , Thomas, Sheeba K. , Treon, Steven P. , Merlini, Giampaolo , Dimopoulos, Meletios A , Terpos, Evangelos , Advani, Ranjana H , Kastritis, Efstathios , Garcia-Sanz, Ramon , Ghobrial, Irene M

Mayo Clinic

Blood | July 16, 2014 | Volume: 124 | Issue: 9 | Pages: 1404-1411

10.1182/blood-2014-03-565135 | PMID 25027391 Get It

Abstract Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of International Workshops on WM (IWWM). As part of the IWWM-7 and based on recently published and ongoing clinical trials, the panels updated treatment recommendations. Therapeutic strategy in WM should be based on individual patient and disease characteristics (age, comorbidities, need for rapid disease control, candidacy for autologous transplantation, cytopenias, IgM-related complications, hyperviscosity, and neuropathy). Mature data show that rituximab combinations with cyclophosphamide/dexamethasone, bendamustine, or bortezomib/dexamethasone provided durable responses and are indicated for most patients. New monoclonal antibodies (ofatumumab), second-generation proteasome inhibitors (carfilzomib), mammalian target of rapamycin inhibitors, and Bruton's tyrosine kinase inhibitors are promising and may expand future treatment options. A different regimen is typically recommended for relapsed or refractory disease. In selected patients with relapsed disease after long-lasting remission, reuse of a prior effective regimen may be appropriate. Autologous stem cell transplantation may be considered in young patients with chemosensitive disease and in newly diagnosed patients with very-high-risk features. Active enrollment of patients with WM in clinical trials is encouraged.
International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
Palumbo, Antonio , Miguel, Jesús F. San , Larocca, Alessandra , Niesvizky, Rubén, Morgan, Gareth J. , Hájek, Roman , Dimopoulos, Meletios Α. , Richardson, Paul G. , Cavo, Michèle , Spencer, Andrew , Stewart, A. Keith, Shimizu, Kazuyuki , Sonneveld, Pieter , Durie, Brian G.M. , Moreau, Philippe , Orlowski, Robert Z. , Rajkumar, S. Vincent , Landgren, Ola , Einsele, Hermann , Anderson, Kenneth C. , Richardson, Paul Gerard Guy , Lonial, Sagar , Orlowski, Robert Z. , Hajek, Roman , Dimopoulos, Meletios A , Moreau, Philippe , San-Miguel, Jesus , Morgan, Gareth J

Mayo Clinic

Journal of Clinical Oncology | January 13, 2014 | Volume: 32 | Issue: 6 | Pages: 587-600

10.1200/jco.2013.48.7934 | PMID 24419113 Get It

Purpose To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation. Methods A comprehensive review of the literature on diagnostic criteria is provided, and treatment options and management of adverse events are summarized. Results Patients with symptomatic disease and organ damage (ie, hypercalcemia, renal failure, anemia, or bone lesions) require immediate treatment. The International Staging System and chromosomal abnormalities identify high- and standard-risk patients. Proteasome inhibitors, immunomodulatory drugs, corticosteroids, and alkylating agents are the most active agents. The presence of concomitant diseases, frailty, or disability should be assessed and, if present, treated with reduced-dose approaches. Bone disease, renal damage, hematologic toxicities, infections, thromboembolism, and peripheral neuropathy are the most frequent disabling events requiring prompt and active supportive care. Conclusion These recommendations will help clinicians ensure the most appropriate care for patients with myeloma in everyday clinical practice.